Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gesunde Ernährung allein reicht oft nicht.
Neubacher D. Neubacher D. MMW Fortschr Med. 2023 Feb;165(3):73. doi: 10.1007/s15006-023-2359-4. MMW Fortschr Med. 2023. PMID: 36759485 German. No abstract available.
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Laffel LM, et al. Among authors: neubacher d. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. Lancet Diabetes Endocrinol. 2023. PMID: 36738751 Free PMC article. Clinical Trial.
Kidney Effects of Empagliflozin in People with Type 1 Diabetes.
Cherney DZI, Bjornstad P, Perkins BA, Rosenstock J, Neubacher D, Marquard J, Soleymanlou N. Cherney DZI, et al. Among authors: neubacher d. Clin J Am Soc Nephrol. 2021 Nov;16(11):1715-1719. doi: 10.2215/CJN.07700621. Epub 2021 Sep 17. Clin J Am Soc Nephrol. 2021. PMID: 34535454 Free PMC article. No abstract available.
Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials.
Lund SS, Sattar N, Salsali A, Neubacher D, Ginsberg HN. Lund SS, et al. Among authors: neubacher d. Diabetes Obes Metab. 2021 Dec;23(12):2763-2774. doi: 10.1111/dom.14534. Epub 2021 Sep 16. Diabetes Obes Metab. 2021. PMID: 34463415 Free PMC article. Clinical Trial.
Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
Perkins BA, Soleymanlou N, Rosenstock J, Skyler JS, Laffel LM, Liesenfeld KH, Neubacher D, Riggs MM, Johnston CK, Eudy-Byrne RJ, Elmokadem A, George JT, Marquard J, Nock V. Perkins BA, et al. Among authors: neubacher d. Diabetes Obes Metab. 2020 Mar;22(3):427-433. doi: 10.1111/dom.13945. Epub 2020 Jan 21. Diabetes Obes Metab. 2020. PMID: 31858718 Free PMC article.
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA. Rosenstock J, et al. Among authors: neubacher d. Diabetes Care. 2018 Dec;41(12):2560-2569. doi: 10.2337/dc18-1749. Epub 2018 Oct 4. Diabetes Care. 2018. PMID: 30287422 Clinical Trial.
24 results